Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; Prexasertib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Prostate cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 15 Jun 2021 During enrollment to the expansion cohort, the study was amended to remove the lead-in of olaparib to avoid unnecessary exposure of patients with PARP inhibitor-resistant tumors to monotherapy as per results published in the Clinical Cancer Research
    • 15 Jun 2021 Based of grade 4 neutropenia lasting for than 7 days or more, the protocol was revised to accommodate intermittent design schedule of Olaparib on days 1-5 and 15-19 in combination with Prexasertib on day 1 & 15 of 28 day cycle as per results published in the Clinical Cancer Research
    • 15 Jun 2021 Results published in the Clinical Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top